174 related articles for article (PubMed ID: 35536841)
1. Clinical experience with hepatorenal tyrosinemia from a single Egyptian center.
El-Karaksy H; Abdullatif HM; Ghobrial CM; Mogahed EA; Yasin NA; Talal N; Rashed M
PLoS One; 2022; 17(5):e0268017. PubMed ID: 35536841
[TBL] [Abstract][Full Text] [Related]
2. Hereditary tyrosinemia type 1 from a single center in Egypt: clinical study of 22 cases.
El-Karaksy H; Fahmy M; El-Raziky M; El-Koofy N; El-Sayed R; Rashed MS; El-Kiki H; El-Hennawy A; Mohsen N
World J Pediatr; 2011 Aug; 7(3):224-31. PubMed ID: 21633861
[TBL] [Abstract][Full Text] [Related]
3. Hepatorenal Tyrosinemia in Mexico: A Call to Action.
Ibarra-González I; Ridaura-Sanz C; Fernández-Lainez C; Guillén-López S; Belmont-Martínez L; Vela-Amieva M
Adv Exp Med Biol; 2017; 959():147-156. PubMed ID: 28755193
[TBL] [Abstract][Full Text] [Related]
4. Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec.
Larochelle J; Alvarez F; Bussières JF; Chevalier I; Dallaire L; Dubois J; Faucher F; Fenyves D; Goodyer P; Grenier A; Holme E; Laframboise R; Lambert M; Lindstedt S; Maranda B; Melançon S; Merouani A; Mitchell J; Parizeault G; Pelletier L; Phan V; Rinaldo P; Scott CR; Scriver C; Mitchell GA
Mol Genet Metab; 2012 Sep; 107(1-2):49-54. PubMed ID: 22885033
[TBL] [Abstract][Full Text] [Related]
5. Type 1 tyrosinemia in Finland: a nationwide study.
Äärelä L; Hiltunen P; Soini T; Vuorela N; Huhtala H; Nevalainen PI; Heikinheimo M; Kivelä L; Kurppa K
Orphanet J Rare Dis; 2020 Oct; 15(1):281. PubMed ID: 33046095
[TBL] [Abstract][Full Text] [Related]
6. Newborn screening for hepatorenal tyrosinemia: Tandem mass spectrometric quantification of succinylacetone.
Sander J; Janzen N; Peter M; Sander S; Steuerwald U; Holtkamp U; Schwahn B; Mayatepek E; Trefz FK; Das AM
Clin Chem; 2006 Mar; 52(3):482-7. PubMed ID: 16439608
[TBL] [Abstract][Full Text] [Related]
7. [Screening for hereditary tyrosinemia and genotype analysis in newborns].
Tong F; Yang R; Liu C; Wu D; Zhang T; Huang X; Hong F; Qian G; Huang X; Zhou X; Shu Q; Zhao Z
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2019 Jun; 48(4):459-464. PubMed ID: 31901053
[TBL] [Abstract][Full Text] [Related]
8. Hepatorenal tyrosinemia.
Kitagawa T
Proc Jpn Acad Ser B Phys Biol Sci; 2012; 88(5):192-200. PubMed ID: 22687740
[TBL] [Abstract][Full Text] [Related]
9. The Québec NTBC Study.
; Alvarez F; Atkinson S; Bouchard M; Brunel-Guitton C; Buhas D; Bussières JF; Dubois J; Fenyves D; Goodyer P; Gosselin M; Halac U; Labbé P; Laframboise R; Maranda B; Melançon S; Merouani A; Mitchell GA; Mitchell J; Parizeault G; Pelletier L; Phan V; Turcotte JF
Adv Exp Med Biol; 2017; 959():187-195. PubMed ID: 28755196
[TBL] [Abstract][Full Text] [Related]
10. Hereditary tyrosinemia type Ⅰ: newborn screening, diagnosis and treatment.
Tang Y; Kong Y
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 50(4):514-523. PubMed ID: 34704422
[TBL] [Abstract][Full Text] [Related]
11. Live donor liver transplantation for type 1 tyrosinemia: An analysis of 15 patients.
Karaca CA; Yilmaz C; Farajov R; Iakobadze Z; Aydogdu S; Kilic M
Pediatr Transplant; 2019 Sep; 23(6):e13498. PubMed ID: 31155831
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations.
Chinsky JM; Singh R; Ficicioglu C; van Karnebeek CDM; Grompe M; Mitchell G; Waisbren SE; Gucsavas-Calikoglu M; Wasserstein MP; Coakley K; Scott CR
Genet Med; 2017 Dec; 19(12):. PubMed ID: 28771246
[TBL] [Abstract][Full Text] [Related]
13. Remaining Challenges in the Treatment of Tyrosinemia from the Clinician's Viewpoint.
Mitchell GA; Yang H
Adv Exp Med Biol; 2017; 959():205-213. PubMed ID: 28755198
[TBL] [Abstract][Full Text] [Related]
14. Biochemical and molecular diagnosis of tyrosinemia type I with two novel FAH mutations in a Hong Kong chinese patient: recommendation for expanded newborn screening in Hong Kong.
Mak CM; Lam CW; Chim S; Siu TS; Ng KF; Tam S
Clin Biochem; 2013 Jan; 46(1-2):155-9. PubMed ID: 23000314
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of pre-symptomatic nitisinone treatment on long-term outcomes in Tyrosinemia type 1 patients: a systematic review.
Geppert J; Stinton C; Freeman K; Fraser H; Clarke A; Johnson S; Sutcliffe P; Taylor-Phillips S
Orphanet J Rare Dis; 2017 Sep; 12(1):154. PubMed ID: 28893311
[TBL] [Abstract][Full Text] [Related]
16. Newborn screening for Tyrosinemia type 1 using succinylacetone - a systematic review of test accuracy.
Stinton C; Geppert J; Freeman K; Clarke A; Johnson S; Fraser H; Sutcliffe P; Taylor-Phillips S
Orphanet J Rare Dis; 2017 Mar; 12(1):48. PubMed ID: 28274233
[TBL] [Abstract][Full Text] [Related]
17. Identification of a neonate with hepatorenal tyrosinemia by combined routine newborn screening for succinylacetone, acylcarnitines and amino acids.
Al-Dirbashi OY; Fisher L; McRoberts C; Siriwardena K; Geraghty M; Chakraborty P
Clin Biochem; 2010 May; 43(7-8):691-3. PubMed ID: 19836366
[No Abstract] [Full Text] [Related]
18. Tyrosinemia type I: clinical and biochemical analysis of patients in Mexico.
Fernández-Lainez C; Ibarra-González I; Belmont-Martínez L; Monroy-Santoyo S; Guillén-López S; Vela-Amieva M
Ann Hepatol; 2014; 13(2):265-72. PubMed ID: 24552869
[TBL] [Abstract][Full Text] [Related]
19. Diagnosing Hepatorenal Tyrosinaemia in Europe: Newborn Mass Screening Versus Selective Screening.
Das AM; Mayorandan S; Janzen N
Adv Exp Med Biol; 2017; 959():125-132. PubMed ID: 28755190
[TBL] [Abstract][Full Text] [Related]
20. Hereditary tyrosinemia type 1 in Turkey: twenty year single-center experience.
Zeybek AC; Kiykim E; Soyucen E; Cansever S; Altay S; Zubarioglu T; Erkan T; Aydin A
Pediatr Int; 2015 Apr; 57(2):281-9. PubMed ID: 25223216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
